In SURPASS-2, tirzepatide was compared directly with semaglutide (another GLP-1 receptor agonist) in patients with type 2 diabetes, with participants continuing background metformin therapy as a requirement for enrollment
Significant weight loss can lead to changes in skin appearance because the skin may not always shrink back completely after being stretched for an extended period
increased production of short-chain fatty acids (SCFAs) can stimulate glucagon-like peptide 1 (GLP-1) secretion, thereby enhancing insulin secretion, improving glucose homeostasis, reducing inflammation, and alleviating T2DM
Additionally, it has the potential to provide a new and effective early diagnostic intervention, thereby improving the chances of successful treatment
Even the risk of mortality from accidents is elevated among the overweight population